JP2024514843A - 発作性疾患を治療するための医薬組成物及び方法 - Google Patents

発作性疾患を治療するための医薬組成物及び方法 Download PDF

Info

Publication number
JP2024514843A
JP2024514843A JP2023561779A JP2023561779A JP2024514843A JP 2024514843 A JP2024514843 A JP 2024514843A JP 2023561779 A JP2023561779 A JP 2023561779A JP 2023561779 A JP2023561779 A JP 2023561779A JP 2024514843 A JP2024514843 A JP 2024514843A
Authority
JP
Japan
Prior art keywords
once
days
seizures
epilepsy
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514843A5 (https=
Inventor
エム． プラコヤニス、フォティオス
ラザー、タマンナ
モディ、ニサーグ
ボロビンスカヤ、マリーナ
Original Assignee
パイク セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/225,654 external-priority patent/US12016829B2/en
Application filed by パイク セラピューティクス インコーポレイテッド filed Critical パイク セラピューティクス インコーポレイテッド
Publication of JP2024514843A publication Critical patent/JP2024514843A/ja
Publication of JP2024514843A5 publication Critical patent/JP2024514843A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023561779A 2021-04-08 2022-04-07 発作性疾患を治療するための医薬組成物及び方法 Pending JP2024514843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/225,654 2021-04-08
US17/225,654 US12016829B2 (en) 2019-10-11 2021-04-08 Pharmaceutical composition and method for treating seizure disorders
PCT/IB2022/053271 WO2022215030A1 (en) 2021-04-08 2022-04-07 Pharmaceutical composition and method for treating seizure disorders

Publications (2)

Publication Number Publication Date
JP2024514843A true JP2024514843A (ja) 2024-04-03
JP2024514843A5 JP2024514843A5 (https=) 2025-04-14

Family

ID=83546168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561779A Pending JP2024514843A (ja) 2021-04-08 2022-04-07 発作性疾患を治療するための医薬組成物及び方法

Country Status (7)

Country Link
EP (1) EP4319730A4 (https=)
JP (1) JP2024514843A (https=)
CN (1) CN117479930A (https=)
AU (1) AU2022255944A1 (https=)
CA (1) CA3213953A1 (https=)
MX (1) MX2023011821A (https=)
WO (1) WO2022215030A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513961A (ja) * 2021-04-12 2024-03-27 パイク セラピューティクス インコーポレイテッド カンナビジオールの経皮送達

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
JP2020059723A (ja) * 2014-06-17 2020-04-16 ジーダブリュー リサーチ リミテッド てんかんの治療におけるカンナビノイドの使用
JP2020533405A (ja) * 2017-09-15 2020-11-19 漢義生物科技（北京）有限公司 カンナビジオール及び／又はカンナビジバリンを含有する組成物及びその月経困難症の治療における使用
JP2020534362A (ja) * 2017-09-19 2020-11-26 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
JP2022551696A (ja) * 2019-10-11 2022-12-13 パイク セラピューティクス，インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
US9962340B2 (en) * 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10821084B2 (en) * 2018-01-31 2020-11-03 Remy Biosciences, Inc. Dihydromyricetin compositions
BR112022004175A2 (pt) * 2019-09-17 2022-05-31 Zynerba Pharmaceuticals Inc Tratamento de encefalopatia de syngap1
KR20230113622A (ko) * 2020-12-03 2023-07-31 지네르바 파마슈티컬스, 인코포레이티드 난치성 발작의 치료를 위한 칸나비디올

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
JP2020059723A (ja) * 2014-06-17 2020-04-16 ジーダブリュー リサーチ リミテッド てんかんの治療におけるカンナビノイドの使用
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
JP2020533405A (ja) * 2017-09-15 2020-11-19 漢義生物科技（北京）有限公司 カンナビジオール及び／又はカンナビジバリンを含有する組成物及びその月経困難症の治療における使用
JP2020534362A (ja) * 2017-09-19 2020-11-26 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2022551696A (ja) * 2019-10-11 2022-12-13 パイク セラピューティクス，インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513961A (ja) * 2021-04-12 2024-03-27 パイク セラピューティクス インコーポレイテッド カンナビジオールの経皮送達

Also Published As

Publication number Publication date
AU2022255944A1 (en) 2023-10-12
EP4319730A1 (en) 2024-02-14
EP4319730A4 (en) 2025-03-12
WO2022215030A1 (en) 2022-10-13
MX2023011821A (es) 2023-10-13
CN117479930A (zh) 2024-01-30
CA3213953A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP7670700B2 (ja) 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US20250248948A1 (en) Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain
JP2023537840A (ja) ナビロンを単独及びカンナビノイドと併用する経皮製剤
US20260076921A1 (en) Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
JP2026009105A (ja) ドロナビノールの経皮送達
JP2023520845A (ja) ヒドロキシクロロキン及び／又はクロロキンを含む経口送達システム
JP2024514843A (ja) 発作性疾患を治療するための医薬組成物及び方法
CN117545478A (zh) 用于治疗慢性疼痛的透皮药物制剂
JP2023521563A (ja) ヒドロキシクロロキン及び／又はクロロキンを含む経皮及び／又は局所送達システム
KR20070059079A (ko) 경피 페로스피론 투여용 의약적 조성물
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders
WO2017029567A1 (en) Transdermal and/or topical delivery system comprising clobazam
US20250381205A1 (en) Transdermal Delivery of Dronabinol
JP2001131089A (ja) 経皮吸収剤
JP2024513961A (ja) カンナビジオールの経皮送達

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210